October 5 – 8, 2026
Westin Seaport
Boston, MA
Collaborate with Caris Life Sciences
Meet the Caris Biopharma team at the World CB & CDx Summit to discuss how deep DNA and RNA molecular insightscan accelerate development and reduce risk. Partner with us to fast-track target discovery, support translational research needs, and develop bespoke therapies and companion diagnostics. To schedule time with our team during the conference, please complete the form.
Panel Discussion
You are cordially invited to attend a thought-provoking discussion on the intersection of AI and companion diagnostics.
The Role of AI in the Future of Companion Diagnostics
Tuesday, October 6
5:10-5:40pm (ET)
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure® delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.